NO20074311L - Kinazolinderivat med tyrosinkinase-inhiberendeaktivitet - Google Patents

Kinazolinderivat med tyrosinkinase-inhiberendeaktivitet

Info

Publication number
NO20074311L
NO20074311L NO20074311A NO20074311A NO20074311L NO 20074311 L NO20074311 L NO 20074311L NO 20074311 A NO20074311 A NO 20074311A NO 20074311 A NO20074311 A NO 20074311A NO 20074311 L NO20074311 L NO 20074311L
Authority
NO
Norway
Prior art keywords
substituted
alkyl group
hydrogen atom
tyrosine kinase
inhibitory activity
Prior art date
Application number
NO20074311A
Other languages
English (en)
Other versions
NO343403B1 (no
Inventor
Masaharu Kume
Kenji Matsuo
Naoki Omori
Masami Takayama
Aiko Omori
Takeshi Endo
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of NO20074311L publication Critical patent/NO20074311L/no
Publication of NO343403B1 publication Critical patent/NO343403B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

En forbindelse representert ved den generelle formel (I) eller et farmasøytisk aksepterbart salt derav eller et solvat av forbindelsen eller saltet: (I) hvor Rx representerer en gruppe representert ved formel (II): hvor representerer et hydrogenatom, en alkylgmppe som kan være substituert eller lignende,. Z representerer -O-, -N(R)- eller lignende, Rrepresenterer et hydrogenatom, en alkylgruppe eller lignende, Rrepresenterer et hydrogenatom, en alkylgruppe som kan være substituert eller lignende, R representerer et hydrogenatom, en alkylgruppe som kan være substituert eller lignende, Rrepresenterer en alkylgruppe som kan være substituert eller lignende, Wrepresenterer en ikke-aromatisk nitrogenert heterocyklisk gruppe som kan være substituert, og Rrepresenterer et hydrogenatom, en alkylgruppe som kan være substituert eller lignende; Rog Rrepresenterer uavhengig et hydrogenatom, en alkylgruppe som kan være substituert eller lignende; X representerer -O-, -S-, -N(R)- eller lignende; R representerer et hydrogenatom, en alkylgruppe eller lignende; og A representerer en fenylgruppe som kan være substituert eller lignende. Forbindelsen kan inhibere både EGF reseptor-tyrosinkinase og HER2 tyrosinkinase.
NO20074311A 2005-02-23 2007-08-23 Kinazolinderivat med tyrosinkinase-inhiberende aktivitet og farmasøytisk sammensetning NO343403B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2005047383 2005-02-23
JP2005156828 2005-05-30
PCT/JP2006/303125 WO2006090717A1 (ja) 2005-02-23 2006-02-22 チロシンキナーゼ阻害作用を有するキナゾリン誘導体

Publications (2)

Publication Number Publication Date
NO20074311L true NO20074311L (no) 2007-11-23
NO343403B1 NO343403B1 (no) 2019-02-25

Family

ID=36927355

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20074311A NO343403B1 (no) 2005-02-23 2007-08-23 Kinazolinderivat med tyrosinkinase-inhiberende aktivitet og farmasøytisk sammensetning

Country Status (16)

Country Link
US (2) US8202879B2 (no)
EP (1) EP1854789B1 (no)
JP (1) JP4137174B2 (no)
KR (1) KR100910333B1 (no)
CN (1) CN101163684B (no)
AU (1) AU2006216266C1 (no)
BR (1) BRPI0606905B1 (no)
CA (1) CA2599328C (no)
DK (1) DK1854789T3 (no)
ES (1) ES2431843T3 (no)
NO (1) NO343403B1 (no)
PL (1) PL1854789T3 (no)
PT (1) PT1854789E (no)
RU (1) RU2414457C2 (no)
TW (1) TWI372147B (no)
WO (1) WO2006090717A1 (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006090717A1 (ja) * 2005-02-23 2006-08-31 Shionogi & Co., Ltd. チロシンキナーゼ阻害作用を有するキナゾリン誘導体
CN101003514A (zh) * 2006-01-20 2007-07-25 上海艾力斯医药科技有限公司 喹唑啉衍生物、其制备方法及用途
US7547781B2 (en) * 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
WO2008033749A2 (en) * 2006-09-11 2008-03-20 Curis, Inc. Quinazoline based egfr inhibitors containing a zinc binding moiety
EP2365962B1 (en) 2008-11-07 2017-07-05 Massachusetts Institute of Technology Aminoalcohol lipidoids and uses thereof
TWI466872B (zh) * 2008-12-25 2015-01-01 Shionogi & Co 喹唑啉衍生物之製造方法
KR102451116B1 (ko) * 2011-10-27 2022-10-06 메사추세츠 인스티튜트 오브 테크놀로지 약물 캡슐화 마이크로스피어를 형성할 수 있는, ｎ-말단 상에 관능화된 아미노산 유도체
CN103288756B (zh) * 2012-02-29 2016-04-20 江苏先声药物研究有限公司 一种喹唑啉中间体的甲醇溶剂合物及其制备方法
CN105407894A (zh) 2013-03-14 2016-03-16 康威基内有限公司 用于抑制含布罗莫结构域的蛋白质的方法和组合物
JP6099182B2 (ja) * 2014-05-29 2017-03-22 塩野義製薬株式会社 アルキニルケトン誘導体の製造方法
JP6334065B2 (ja) * 2015-07-29 2018-05-30 塩野義製薬株式会社 キナゾリン誘導体の塩またはその結晶およびそれらの製造方法
CA3000988A1 (en) 2015-10-05 2017-04-13 The Trustees Of Columbia University In The City Of New York Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies
CN115806550A (zh) * 2015-11-25 2023-03-17 康威基内有限公司 双环bet布罗莫结构域抑制剂及其用途
US20180030403A1 (en) 2016-07-28 2018-02-01 Bobban Subhadra Devices, systems and methods for the production of humanized gut commensal microbiota
JP7191446B2 (ja) * 2017-01-30 2022-12-19 塩野義製薬株式会社 キナゾリン誘導体を含有する固形製剤

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2102780C (en) 1991-05-10 2007-01-09 Alfred P. Spada Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
GB9323290D0 (en) 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
EP3103799B1 (en) * 1995-03-30 2018-06-06 OSI Pharmaceuticals, LLC Quinazoline derivatives
GB9624482D0 (en) * 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
PT912559E (pt) 1996-07-13 2003-03-31 Glaxo Group Ltd Compostos heterociclicos fundidos como inibidores de proteina tirosina quinase
HUP0204413A3 (en) 1999-09-21 2003-07-28 Astrazeneca Ab Quinazoline compounds, their preparation, their use and pharmaceutical compositions containing them
CN1264824C (zh) 2001-02-21 2006-07-19 三菱制药株式会社 喹唑啉衍生物
WO2003031406A2 (en) 2001-10-12 2003-04-17 Irm Llc Kinase inhibitor scaffolds and methods for their preparation
CA2497971A1 (en) 2002-09-18 2004-04-01 Pfizer Products Inc. Triazole derivatives as transforming growth factor (tgf) inhibitors
WO2004069145A2 (en) 2003-02-07 2004-08-19 Dr. Reddy's Laboratories Ltd. Anticancer compounds, process for their preparation and pharmaceutical compositions containing them
PA8603801A1 (es) 2003-05-27 2004-12-16 Janssen Pharmaceutica Nv Derivados de la quinazolina
WO2005067667A2 (en) 2004-01-07 2005-07-28 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
US8017321B2 (en) 2004-01-23 2011-09-13 The Regents Of The University Of Colorado, A Body Corporate Gefitinib sensitivity-related gene expression and products and methods related thereto
WO2006090717A1 (ja) * 2005-02-23 2006-08-31 Shionogi & Co., Ltd. チロシンキナーゼ阻害作用を有するキナゾリン誘導体

Also Published As

Publication number Publication date
EP1854789A4 (en) 2009-06-17
US20090143414A1 (en) 2009-06-04
AU2006216266C1 (en) 2010-08-26
BRPI0606905A2 (pt) 2009-07-28
CA2599328C (en) 2012-04-17
RU2007135023A (ru) 2009-03-27
AU2006216266B2 (en) 2010-02-18
AU2006216266A2 (en) 2006-08-31
CA2599328A1 (en) 2006-08-31
EP1854789A1 (en) 2007-11-14
TW200640880A (en) 2006-12-01
EP1854789B1 (en) 2013-10-09
CN101163684A (zh) 2008-04-16
JP4137174B2 (ja) 2008-08-20
ES2431843T3 (es) 2013-11-28
CN101163684B (zh) 2012-08-29
DK1854789T3 (da) 2013-10-21
KR20070098941A (ko) 2007-10-05
US8349857B2 (en) 2013-01-08
AU2006216266A8 (en) 2009-04-02
PL1854789T3 (pl) 2014-03-31
TWI372147B (en) 2012-09-11
US8202879B2 (en) 2012-06-19
US20120123114A1 (en) 2012-05-17
JPWO2006090717A1 (ja) 2008-07-24
NO343403B1 (no) 2019-02-25
PT1854789E (pt) 2013-10-23
RU2414457C2 (ru) 2011-03-20
KR100910333B1 (ko) 2009-07-31
BRPI0606905B1 (pt) 2021-06-01
AU2006216266A1 (en) 2006-08-31
WO2006090717A1 (ja) 2006-08-31

Similar Documents

Publication Publication Date Title
NO20074311L (no) Kinazolinderivat med tyrosinkinase-inhiberendeaktivitet
WO2005110410A3 (en) Kinase inhibitors as therapeutic agents
NO20073956L (no) Pyrazolderivater for inhibering av CDK og GSK
WO2005074603A3 (en) Aminobenzoxazoles as therapeutic agents
NO20070557L (no) Ftalazinderivater som PARP-inhibitorer
TW200618800A (en) Heterocyclic compounds
EA200801381A1 (ru) Производные пиримидина
WO2007016392A3 (en) Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors
NO20063501L (no) Kinolinintermediater av reseptor-Tyrosin-Kinase-inhibitorer og deres syntese
NO20080675L (no) P38-Map kinaseinhibitorer og metoder for deres anvendelse
NO20082482L (no) Karbonylamino pyrrolpyrazoler, samt anvendelse som kinase inhibitorer
NO20073926L (no) Pyrazolforbindelser som modulerer aktivitet av CDK-, GSK- og aurorakinaser
NO20070532L (no) Substituerte 2-alkyl-kinazolinonderivater som PARP-inhibitorer
NO20092770L (no) Nye aminopyrimidinderivater som PLK1-inhibitorer
TNSN08089A1 (en) Substituted benzimidazoles and methods of preparation
ATE553106T1 (de) Heteroarylpyrrolopyridinone als kinaseinhibitoren
NO20083923L (no) Pyrazolkinoloner er potente parp-inhibitorer
NO20062185L (no) Hepatitt C virus-inhibitorer
WO2008087933A1 (ja) ＩκＢキナーゼβ阻害活性を有する新規インドール誘導体
NO20092286L (no) Nitrogenhaldige heterosykliske forbindelser og anvendelse derav
NO20084583L (no) Makrosykliske kinase-inhibitorer
DE602006011752D1 (de) Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate
TW200637539A (en) CTGF inhibitors
NO20065327L (no) Fremgangsmate for fremstilling av derivarer av 5-'4-(2-hydroksy-propyl)-3,5-dihydro-3H'1, 2,4(triazin-2-yl)-benzamid.
NO20072753L (no) 3-Etylidenhydrazinosubstituerte heterocykliske forbindelser som trombopoietinreseptoraktivatorer